STOCK TITAN

Absci to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, has announced its participation in three upcoming investor conferences in September 2024:

  • Morgan Stanley 22nd Annual Global Healthcare Conference: Fireside chat on September 5th at 5:35 p.m. ET
  • Citi 2024 Global TMT Conference: Fireside chat on September 6th at 8:20 a.m. ET
  • H.C. Wainwright 26th Annual Global Investment Conference: Fireside chat on September 10th at 12:00 p.m. ET

Interested parties can access live and archived webcasts of these events on Absci's investor relations website at investors.absci.com.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction

+2.84%
1 alert
+2.84% News Effect

On the day this news was published, ABSI gained 2.84%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

VANCOUVER, Wash. and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.

  • Morgan Stanley 22nd Annual Global Healthcare Conference
    Fireside chat on Thursday, September 5th at 5:35 p.m. Eastern Time
  • Citi 2024 Global TMT Conference
    Fireside chat on Friday, September 6th at 8:20 a.m. Eastern Time
  • H.C. Wainwright 26th Annual Global Investment Conference
    Fireside chat on Tuesday, September 10th at 12:00 p.m. Eastern Time

Interested parties may access live and archived webcasts of these events on the company’s investor relations website at: investors.absci.com.

About Absci

Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.

Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com

Media Contact
press@absci.com


FAQ

What investor conferences will Absci (ABSI) participate in during September 2024?

Absci (ABSI) will participate in three investor conferences in September 2024: Morgan Stanley 22nd Annual Global Healthcare Conference, Citi 2024 Global TMT Conference, and H.C. Wainwright 26th Annual Global Investment Conference.

When is Absci's (ABSI) fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference?

Absci's (ABSI) fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference is scheduled for Thursday, September 5th, 2024, at 5:35 p.m. Eastern Time.

How can investors access Absci's (ABSI) conference webcasts?

Investors can access live and archived webcasts of Absci's (ABSI) conference events on the company's investor relations website at investors.absci.com.

What type of company is Absci (ABSI) described as in the press release?

Absci (ABSI) is described as a data-first generative AI drug creation company in the press release.
Absci Corp

NASDAQ:ABSI

ABSI Rankings

ABSI Latest News

ABSI Latest SEC Filings

ABSI Stock Data

475.17M
136.23M
9.25%
60.02%
21.14%
Biotechnology
Services-commercial Physical & Biological Research
Link
United States
VANCOUVER